About Semaglutide
Semaglutide is a synthetic GLP-1 receptor agonist used in metabolic and endocrine research. Supplied as a lyophilized powder for laboratory investigations of incretin receptor pharmacology, glucose-regulatory signaling, and downstream pathway activity in controlled experimental systems. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99(HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.
Recent research on Semaglutide: Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.
Read Full Study on PubMedShort-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
Recent research on Semaglutide: Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
Read Full Study on PubMedAdditional Studies
Semaglutide-associated Twiddler syndrome.
Recent research on Semaglutide: Semaglutide-associated Twiddler syndrome.
Read on PubMed[Advances in Anti-Dementia Therapies in Older Adults].
Recent research on Semaglutide: [Advances in Anti-Dementia Therapies in Older Adults].
Read on PubMedGLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
Recent research on Semaglutide: GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
Read on PubMedTranscriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
Recent research on Semaglutide: Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
Read on PubMedGlucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
Recent research on Semaglutide: Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
Read on PubMedOrforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
Recent research on Semaglutide: Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
Read on PubMedRelated Research
Purchase Semaglutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.